286
Views
13
CrossRef citations to date
0
Altmetric
SHORT REPORT

A pilot trial with clenbuterol in amyotrophic lateral sclerosis

, , , , , , , & show all
Pages 252-254 | Received 15 Sep 2005, Accepted 24 Jan 2006, Published online: 10 Jul 2009

References

  • Swash M. Clinical features and diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis, R. H Jr Brown, V Meininger, M Swash. Martin Dunitz, London 2000; 330
  • Hinkle R. T., Hodge K. M., Cody D. B., Sheldon R. J., Kobilka B. K., Isfort R. J. Skeletal muscle hypertrophy and anti‐atrophy effects of clenbuterol are mediated by beta 2‐adrenergic receptor. Muscle Nerve 2002; 25: 729–34
  • Fukumoto H., Kakihana M., Suno M. Characterization of C6‐10A glioma cells highly responsive to beta adrenergic receptor agonist induced NGF synthesis/secretion. Glia 1994; 12: 151–60
  • Semkova I., Schilling M., Henrich‐Noack P., Rami A., Krieglstein J. Clenbuterol protects mouse cerebral cortex and rat hippocampus from ischaemic damage and attenuates glutamate neurotoxicity in cultured hippocampal neurons by induction of NGF. Brain Res 1996; 717: 44–54
  • Uc E. Y., Dienel G. A., Cruz N. F., Harik S. I. Adrenergics enhance brain extraction of levodopa. Mov Disord 2002; 17: 54–9
  • Agbenyega E. D., Wareham A. C. Effect of clenbuterol on normal and denervated muscle growth and contractility. Muscle Nerve 1990; 13: 199–203
  • Maltin C. A., Delday M. I., Watson J. S., Heys S. D., Nevison I. M., Ritchie I. K., et al. Clenbuterol, a beta adrenoreceptor agonist, increases relative muscle strenghth in orthopaedic patients. Clin Sci 1993; 4: 651–4
  • Kinali M., Mercuri E., Main M., De Biasia F., Karatza A., Higgins R., et al. Pilot trial with albuterol in spinal muscular atrophy. Neurology 2002; 59: 609–10
  • Juhasz‐Pocsine K., Merryfield J. J., Sanjak M., Belden D. S., Waclawik A. J., Brooks B. R. Beta 2‐adrenergic agonist (Albuterol) ergotropic effect on neck extension (NE) and neck flexion (NF) maximal voluntary isometric contraction (MVIC) strength in amyotrophic lateral sclerosis (ALS) patients: quasi‐experimental prospective non‐randomized control pilot studies using Medical Research Council (MRC) grading scale and computerized isometric muscle testing (CIMT). Neurology 1999; 52 (6 Suppl. 2): A526
  • Signorile J. F., Banovac K., Gomez M., Flipse D., Caruso J. F., Lowensteyn I. Increased muscle strength in paralysed patients after spinal cord injury: effect of beta 2‐adrenergic agonists. Arch Phys Med Rehabil 1995; 76: 55–8
  • World Federation of Neurology Research Committee on Neuromuscular Diseases and Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis. El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994; 124: 96–107
  • Cedarbaum J. M., Stambler N. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicentre clinical trials. J Neurol Sci 1997; 152((Suppl. 1))S1–9
  • Frisancho A. R., Flegel P. N. Relative merits of old and new indices of body mass with reference to skin‐folds thickness. Am J Clin Nutr 1982; 36: 697–9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.